Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

White paper on lab-produced cannabinoids

22 Apr 2022 07:00

RNS Number : 9842I
Cellular Goods PLC
22 April 2022
 

Press release 

 

22 April 2022

 

Cellular Goods PLC

 

('Cellular Goods' or 'the Company')

 

Publication of white paper on sustainability of lab-produced cannabinoids

 

Cellular Goods (LSE: CBX), a UK-based wellness company that provides premium products formulated with lab-made cannabinoids, today announces the publication of a new white paper, 'Production of Cannabinoids Using Biotechnology and Synthetic Chemistry as a Path to Sustainability', which explores the improved sustainability and increased purity of lab-based production of cannabinoids when compared with traditional agricultural production.

 

Until recently, global demand for cannabinoids, primarily driven by sales of cannabidiol (CBD), has been satisfied by agricultural cultivation of the cannabis sativa plant from which these are extracted. However, this is a highly inefficient process. Cannabinoids make up just 2-5% of the plant by mass, which leads to approximately 90% of the plant ending up as botanical waste. Additionally, agricultural production is plagued by high land and water use, yield variability, potential microbial and chemical contamination and crop loss.

 

With the global market for CBD increasing by an annual compound growth rate of 21.3%, the market is expected to grow from US$4.9 billion in 2021 to US$47.22 billion by 2028, according to Vantage Market Research. Attempting to satisfy this increased demand with agricultural methods is likely to have a significant environmental cost and cause a production bottleneck, the white paper warns. (Source: Vantage Market Research, 2022, Cannabidiol Market Projected to Reach Valuation of USD 47.22 Billion by 2028).

 

Cellular Goods' white paper also reveals that biotechnology and synthetic chemistry allow cannabinoids to be produced at a commercial scale with increased purity, upwards of 95%, and significantly decreased environmental drawbacks compared with agricultural production. To produce 1,000kg of cannabigerol (CBG), a rare breakthrough cannabinoid, outdoor production requires 208% more time, and requires 40 acres of land, where lab-based production requires less than one acre. Furthermore, in outdoor CBD production, Carbon Dioxide (CO2) emissions are 44 times higher than by biosynthesis and requires 333 times more water. For biomass waste, biosynthesis produces 99.93% less waste than agricultural production.

 

Cellular Goods' products are exclusively formulated with lab-produced cannabinoids, and this white paper demonstrates how the Company remains committed to ethically and sustainably sourcing the components of its products.

 

The white paper is available to view here.

 

Anna Chokina, Chief Executive Officer, commented: "The publication of today's white paper illustrates our continued commitment to creating environmentally conscious, efficacy-led products. Cellular Goods exclusively uses lab-produced cannabinoids in its products, and this decision is fully vindicated by this white paper.

 

"Not only is the production process more sustainable, requiring less land, water and producing greatly decreased biomass waste and carbon emissions than agricultural production, but lab production gives the opportunity to increase production without suffering systemic and biological restraints. Use of lab production provides a greater ability to respond to any increases in demand in the cannabinoid space, as consumers become increasingly conscious of the effective skincare and wellness applications of cannabinoids."

 

Istok Nahtigal, Head of Process and Applied Sciences, commented: "Our research has further evidenced Cellular Goods' existing belief that lab-production methods for producing cannabinoids are the future. As consumers become increasingly environmentally conscious, it is important to prioritise ecological methods of production. Lab-production is a win-win for the Company, as it is not only more sustainable, but produces purer, higher quality products."

 

 

For further information please contact:

 

Cellular Goods

Anna Chokina

Chief Executive

Neil Thapar

Investor Relations

via Tancredi +44 207 887 7633

 

+44 787 645 5323

Tennyson Securities

Corporate Broker

Peter Krens

 

+44 207 186 9030

Novum Securities

Corporate Broker

Colin Rowbury

Jon Belliss

 

 

+44 207 399 9427 

Tancredi Intelligent Communication

Media Relations

Helen Humphrey

Gabriela Amaya Garcia

Charlie Hobbs

cellulargoods@tancredigroup.com

 

+44 744 922 6720

+44 791 503 5294

+44 789 755 7112

 

About Cellular Goods PLC:

Cellular Goods is a UK-based wellness company that provides premium products based on lab-made cannabinoids. It was established in August 2018 to develop efficacy-led and research-backed cannabinoid-powered wellness products. The initial focus is on three product verticals: Function Better, Feel Better and Look Better. These three verticals encompass Cellular's premium CBG skincare and CBD ingestible and topical athletic recovery products, with the first products launched in December 2021 initially through the Company's website. The Company's shares are listed on the main market of the London Stock Exchange. www.cellular-goods.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAPPUWWCUPPPWG
Date   Source Headline
28th Mar 20224:35 pmRNSPrice Monitoring Extension
28th Mar 202211:00 amRNSPrice Monitoring Extension
22nd Mar 20227:00 amRNSDirectorate change
14th Mar 20224:41 pmRNSSecond Price Monitoring Extn
14th Mar 20224:36 pmRNSPrice Monitoring Extension
14th Mar 20222:05 pmRNSSecond Price Monitoring Extn
14th Mar 20222:00 pmRNSPrice Monitoring Extension
14th Mar 20227:00 amRNSLaunch of outdoor marketing campaign
8th Mar 202211:03 amRNSShare purchase by CEO
7th Mar 202211:05 amRNSSecond Price Monitoring Extn
7th Mar 202211:00 amRNSPrice Monitoring Extension
4th Mar 20224:41 pmRNSSecond Price Monitoring Extn
4th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSExercise of Warrants
1st Mar 20227:00 amRNSLaunch of Rejuvenating Cannabinoid Face Serum
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
23rd Feb 20222:06 pmRNSSecond Price Monitoring Extn
23rd Feb 20222:01 pmRNSPrice Monitoring Extension
21st Feb 202211:05 amRNSSecond Price Monitoring Extn
21st Feb 202211:00 amRNSPrice Monitoring Extension
21st Feb 20229:05 amRNSSecond Price Monitoring Extn
21st Feb 20229:00 amRNSPrice Monitoring Extension
21st Feb 20227:00 amRNSStrategy and trading update
2nd Feb 20227:00 amRNSWhite paper on cannabinoids and skin aging
7th Jan 20221:00 pmRNSResults of Annual General Meeting
15th Dec 20217:00 amRNSAnnual General Meeting update
8th Dec 20217:00 amRNSGrant of Options to CEO
6th Dec 20211:57 pmRNSPosting of Annual Report and Notice of AGM
6th Dec 20217:00 amRNSAppointment of new CEO
3rd Dec 20217:00 amRNSAnnual results
1st Dec 20217:00 amRNSLaunch of inaugural products & ecommerce platform
11th Nov 20217:00 amRNSAdvertising and PR agencies appointed
8th Nov 20212:05 pmRNSSecond Price Monitoring Extn
8th Nov 20212:00 pmRNSPrice Monitoring Extension
8th Nov 202111:05 amRNSSecond Price Monitoring Extn
8th Nov 202111:00 amRNSPrice Monitoring Extension
1st Nov 20217:00 amRNSGrant of Share Options and update on warrants
4th Oct 20219:06 amRNSSecond Price Monitoring Extn
4th Oct 20219:00 amRNSPrice Monitoring Extension
4th Oct 20217:00 amRNSDirector dealings & TR1 notification
16th Aug 20217:00 amRNSSupply agreement signed with Chanelle McCoy Health
2nd Aug 20217:00 amRNSShare disposal by significant shareholder
28th Jul 20212:06 pmRNSSecond Price Monitoring Extn
28th Jul 20212:00 pmRNSPrice Monitoring Extension
10th Jun 20217:00 amRNSSupply agreement signed with Willow Biosciences
25th May 20217:00 amRNSCellular Goods Interim Results
6th May 20217:00 amRNSGrant of Warrants and Extension of Exercise Period
20th Apr 20212:00 pmRNSPrice Monitoring Extension
12th Apr 20217:00 amRNSCellular Goods boosts team with five appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.